Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 18, 2026, the Board of Directors of OPKO Health, Inc. (the "Company"), appointed Subbarao V. Uppaluri, Ph.D. as a new director with immediate effect to serve until the Company's 2026 Annual Meeting of Stockholders and until his successor shall be duly elected or appointed or his earlier death or resignation. Dr. Uppaluri is expected to be appointed to the Compensation Committee of the Board. There is no arrangement or understanding between Dr. Uppaluri and any other persons pursuant to which Dr. Uppaluri was selected as a director. The Board has determined that Dr. Uppaluri is independent under the applicable rules of the Securities and Exchange Commission and the Nasdaq Stock Market.

Dr. Uppaluri served as Senior Vice President and Chief Financial Officer of the Company from May 2007 until his retirement in July 2012 and as a consultant of the Company until February 2014. He served as the Vice President, Strategic Planning and Treasurer of IVAX from 1997 until December 2006. Dr. Uppaluri served in various positions, including Senior Vice President, Senior Financial Officer, Chief Investment Officer, and Controller with several publicly traded banks and began his career in engineering, marketing and research positions with multinational companies and research institutes in India and the United States. Dr. Uppaluri currently serves on the board of Baptist Health Homestead Hospital. Dr. Uppaluri previously served on the boards of Non-Invasive Monitoring Systems, Inc. from 2008 until 2025 and several other publicly traded companies.

Since the beginning of the Company's last fiscal year, the Company has not engaged in any transaction, or any currently proposed transaction, in which Dr. Uppaluri had or will have a direct or indirect material interest that would require disclosure pursuant to Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission.

Dr. Uppaluri will participate in the standard non-employee director compensation arrangements described in the section entitled "Director Compensation" that is included in the Company's 2025 Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 14, 2025. The Company has also entered into its standard director indemnification agreement with Dr. Uppaluri, a form of which has been filed or incorporated by reference as Exhibit 10.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 2, 2020.

Dr. Uppaluri was appointed to the Board of Directors due to a vacancy as a result of the passing of Dr. Richard Krasno who served on the Company's Board of Directors beginning in February 2017.